Evidence map›Paper›PMID 26699899›Full record

Trial reportHeart and vessels2016

Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial).

Mitsuhiro Shimomura, Jun-Ichi Oyama, Masayoshi Takeuchi, Yoshisato Shibata, Yusuke Yamamoto, Tomohiro Kawasaki, Hiroshi Komoda, Kazuhisa Kodama, Masashi Sakuma, Shigeru Toyoda and 8 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Mitsuhiro ShimomuraDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Jun-Ichi OyamaDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan. junoyama@cc.saga-u.ac.jp.
Masayoshi TakeuchiDepartment of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan.
Yoshisato ShibataDepartment of Cardiology, Miyazaki Medical Association Hospital, Miyazaki, Japan.
Yusuke YamamotoDivision of Cardiology, Cardiovascular and Aortic Center, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Tomohiro KawasakiCardiovascular Center, Shin-Koga Hospital, Fukuoka, Japan.
Hiroshi KomodaDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Kazuhisa KodamaDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Masashi SakumaDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Shigeru ToyodaDepartment of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Tochigi, Japan.
Yohei InoueDepartment of Cardiology, Miyazaki Medical Association Hospital, Miyazaki, Japan.
Daigo MineDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Masahiro NatsuakiDivision of Cardiology, Cardiovascular and Aortic Center, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Aiko KomatsuDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Yutaka HikichiDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Sho-Ichi YamagishiDepartment of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Fukuoka, Japan.
Teruo InoueDepartment of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Tochigi, Japan.
Koichi NodeDepartment of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Saga University · JPDokkyo Medical University · JPSaiseikai Fukuoka General Hospital · JPKanazawa Medical University · JPKoga Hospital · JPKurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Experimental ischemia-reperfusion models have shown that 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, statins, have cardioprotective effects. SAMIT (Statin Acute Myocardial Infarction Trial) is a multicenter prospective open randomized trial, designed to evaluate the effects of statin treatment from the earliest stage on cardioprotection in patients with acute myocardial infarction (AMI). Patients were randomly assigned to receive atorvastatin (initial dose of 40 mg at admission followed by the maintenance dose of 10 mg/day for 30 days) or not (control), and then immediately underwent percutaneous coronary intervention (PCI) for the culprit lesion. The primary endpoints were infarct size and left ventricular function. The secondary endpoints were major adverse cardiac and cerebrovascular events (MACCE) and various biomarkers. There were no significant differences in baseline characteristics between 2 groups of the statin treatment group and the control group. The left ventricular ejection fraction increased at 6 months after the onset of AMI, compared with the baseline level in the atorvastatin group (P < 0.05), while it did not change in the control group. Although there were no significant differences in the MACCE, the changes in the levels of angiopoietin-like protein 2 (ANGPTL2) (P < 0.05), and glyceraldehyde-derived advanced glycation end-products, (TAGE) (P < 0.01) were suppressed at 2 weeks in the atorvastatin group, compared with the control group. Statin therapy started early after the onset reduced the levels of ANGPTL2 and TAGE, and thus, might have cardioprotective effects in patients with AMI.

Indexed as

Angioplasty, Balloon, CoronaryAcute DiseaseAgedAngiopoietin-Like Protein 2Angiopoietin-like ProteinsAngiopoietinsAtorvastatinFemaleGlycation End Products, AdvancedHumansHydroxymethylglutaryl-CoA Reductase InhibitorsJapanMaleMiddle AgedMyocardial InfarctionOxidative StressAngiopoietin-Like Protein 2Angiopoietin-like ProteinsAngiopoietinsANGPTL2 protein, humanAtorvastatinGlycation End Products, AdvancedHydroxymethylglutaryl-CoA Reductase InhibitorsAcute myocardial infarctionInflammationOxidative stressStatin

Identifiers

PMID26699899
OpenAlexW2232854731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.